All that glitters is not gold: a case report of a diffuse peritoneal aspergillosis

Cristian Tefas1,2, Bobe Petrushev3, Cristina Pojoga1, Radu Badea2,4

1Gastroenterology Department “Octavian Fodor” Institute of Gastroenterology and Hepatology, 2“Iuliu Hatieganu” University of Medicine and Pharmacy, 3Pathology Department “Octavian Fodor” Institute of Gastroenterology and Hepatology, 4Ultrasonography Department “Octavian Fodor” Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania

Abstract

Invasive aspergillosis is a rare disease, more frequently encountered in immunocompromised patients. We report a case of diffuse peritoneal aspergillosis. A 56-year old female with a history of recent renal transplantation was admitted with a suspicion of peritoneal carcinomatosis following a native computed tomography scan. Gray scale abdominal ultrasound showed multiple peritoneal masses. Upon performing contrast-enhanced ultrasound these masses demonstrated peripheral arterial enhancement and slow wash-out during the venous phase. The final histopathological examination confirmed a diagnosis of peritoneal aspergillosis. Gray scale ultrasonography in combination with contrast-enhanced ultrasonography is useful in the evaluation of intraabdominal masses. The procedures are of great value especially in patients with a high risk of contrast-induced nephropathy where contrast-enhanced CT or MRI are contraindicated.

Keywords: aspergillosis; carcinomatosis; peritoneum; contrast-enhanced ultrasound

Introduction

Aspergillosis comprises a variety of diseases caused by fungal infections from species of Aspergillus, with A. fumigatus and A. flavus being the most frequent [1,2]. The resulting illnesses usually affect the respiratory system. However, in immunocompromised patients, such as those with hematological malignancies, recipients of hematopoietic stem cells or solid organ transplantation, Aspergillus may cause many clinical forms. Diagnosis is usually made by serological, histopathological or imaging tests, while treatment strategies include corticosteroids and antifungal medication sometimes in combination with surgical debridement [3–6].

We present a case of peritoneal aspergillosis in a patient with a recent renal transplantation. We emphasize the importance of contrast-enhanced ultrasonography (CEUS) in the evaluation of intraabdominal masses in patients where intravenous contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) are not available or they cannot be performed because of acute or chronic kidney injury.

Case report

A 56-year old female patient with a history of hepatorenal polycystic disease, right nephrectomy and renal transplantation four months previously, was admitted to our gastroenterology unit with the suspicion of peritoneal carcinomatosis. This diagnosis was raised after performing a native CT scan in another hospital. The patient complained of diffuse abdominal pain and a 20-kilogram
All that glitters is not gold: a case report of a diffuse peritoneal aspergillosis

weight loss over the past weeks. Post-transplant immunosuppression was attained using a combination treatment of a calcineurin inhibitor and corticosteroids.

Physical examination revealed pallor and a diffusely enlarged abdomen. Laboratory tests revealed moderate grade anemia (Hb = 8.7 g/dl), hyperglycemia (209 mg/dl), hypoalbuminemia (2.9 g/dl) and an increase in creatinine levels (1.72 mg/dl) with a glomerular filtration rate (eGFR) of 37 ml/min.

Imaging evaluation started with conventional gray-scale abdominal ultrasound (US) which showed multiple nonhomogeneous hypoechoic masses on the peritoneum and in the left lower flank abdominal wall, up to 35 mm in size (fig 1a). Follow-up CEUS was then performed and 1.6 ml of contrast agent (Sonovue – Bracco SpA, Milan, Italy) was injected, followed by a 10-cc bolus of saline. A mechanical index of 0.10 was used. The exploration was continuous for 5 minutes using longitudinal and transversal section planes of the abdomen. The peritoneal masses showed peripheral arterial enhancement, starting at 13 seconds after contrast-agent injection, with slow washout during the late venous phase (around 120 seconds) (fig 1b,c). Gray-scale US and CEUS were performed using a General Electric LOGIQ E9 imaging system. EFSUMB recommendations were respected [7].

A US-guided percutaneous biopsy from one of the peritoneal masses was performed using a Bard Magnum biopsy system (Bard Biopsy, Tempe, Arizona, USA) with a 16G needle, producing a 5 mm tissue fragment. Subsequent histopathological examination with a Leica DM1000 microscope and a Leica CMOS DMC5400 camera using hematoxylin-eosin staining showed an inflammatory background and numerous hyphae with the tendency to form “masses” (fig 2a). Follow up periodic acid-Schiff (PAS) and Grocott’s methenamine silver (GMS) stains confirmed the diagnosis of aspergillosis (fig 2b).

The patient was then transferred to an infectious diseases unit where she underwent systemic antifungal treatment with a good outcome.

Discussion

In the case of peritoneal solid nodules, the first diagnosis to be usually considered is peritoneal carcinomatosis. However, there are a number of differential diagnoses to be taken into account, including infectious conditions. This case highlights how a prompt diagnosis is essential for a good patient outcome.

In immunocompromised patients, such as those who undergo therapeutic immunosuppression after organ
transplantation, aspergillosis is the most frequent type of mold infections. In these patients, the most common form is pulmonary, which can subsequently disseminate, leading to organ failure, with death rates that can reach 90-100% [8,9]. Aspergillus peritonitis is very rare and usually encountered in patients undergoing peritoneal dialysis [8]. Risk factors associated with invasive aspergillosis after kidney transplantation include prolonged high dose corticosteroids, immunosuppressive therapy and graft failure [10]. To our knowledge, this is the first reported case of peritoneal aspergillosis in a patient who had undergone renal transplantation.

Invasive aspergillosis is frequently misdiagnosed as the clinical symptoms and physical findings are non-specific. Imaging findings are variable and transient. The halo sign is a characteristic finding on imaging studies and denotes nodules with surrounding ground-glass infiltrates [11,12]. These appear because of bleeding into the area surrounding the fungus and can be encountered in only up to 60% of patients, disappearing within a week. The air-crescent sign, which is secondary to the enlargement and cavitation of these nodules appears only after 3 weeks of illness [12].

In the reported case, the native CT scan showed multiple peritoneal nodules, well depicted in the greater omentum, suggesting the presence of peritoneal carcinomatosis. However, due to the patient’s renal impairment, an intravenous contrast agent could not be used to further characterize the nodules.

CEUS showed peripheral arterial enhancement with a slow wash-out phase, similar to the behavior of an abscess. Due to the absence of any previous or current neoplasia in this patient and her immunocompromised status, CEUS was paramount in reorienting the diagnosis suggesting a more probable infectious cause for the peritoneal masses. In the absence of CEUS, having a suspicion of peritoneal carcinomatosis in mind, the patient would have been submitted to a series of costly and invasive procedures, with no additional benefit.

In conclusion, although the most common diagnosis of peritoneal masses is that of peritoneal carcinomatosis, we must always take into consideration other causes, especially in immunocompromised patients, where systemic opportunistic infections may appear, in order to send the patient for the right treatment in a timely manner.

Acknowledgements: The authors thank Mrs. Szasz Zsoka for her involvement in the follow-up of the patient.

References
1. Taccone FS, Van den Abeele AM, Bulpa P, et al. Epidemiology of invasive aspergillosis in critically ill patients: Clinical presentation, underlying conditions, and outcomes. Crit Care 2015;19:7.
2. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: Epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007;67:1567–601.
3. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350–1360.
4. Walsh TJ1, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360.
5. Cornely OA, Maertens J, Bresnik M, et al. Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Clin Infect Dis 2007;44:1289–1297.
6. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.
7. Piscaglia F, Nolsøe C, Dietrich CF, et al. The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): Update 2011 on non-hepatic applications. Ultraschall Medizin 2012;33:33–59.
8. Mûoz P, Guinea J, Bouza E. Update on invasive aspergillosis: Clinical and diagnostic aspects. Clin Microbiol Infect 2006;12:24–39.
9. Davies S, Guidry C, Politano A, et al. Aspergillus infections in transplant and non-transplant surgical patients. Surg Infect (Larchmt) 2014;15:207–212.
10. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005;18:44–69.
11. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011;52:1144–1155.
12. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001;19:253–259.